and our laboratories have shown that knockdown and pharmacological inhibition of MAGL—the enzyme that is responsible for the degradation of 2-AG [15, 32, 40]—inhibited the in vitro and in vivo growth of primary bone sarcoma and reduced the metastatic spread and bone damage associated with prostate and breast cancer [27, 32, 34]. Here, MGLL is linked to breast carcinoma.